Artiva Biotherapeutics

IPO

NK Cell Therapy for Autoimmune Disease and Cancer

Public · San Diego, United States · Founded 2019

Headquarters
San Diego
Founded
2019
Business Model
B2B
Last Round
Series BFeb 2021
Rounds
3
Type
Public

About

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural-killer-cell therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved, allogeneic NK-cell therapy evaluated with B-cell-targeted monoclonal antibodies. The company is testing it across three clinical trials, including company-sponsored and investigator-initiated studies of B-cell-driven autoimmune diseases.

Summary

Artiva Biotherapeutics is a Biotech company based in San Diego, United States, founded in 2019. Its most recent funding was a Series B round in Feb 2021. Investors include venBIO Partners, Venrock and 5AM Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketMay 2026

Sign up to see all 5 rounds

Seed through Secondary Market — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Artiva Biotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/artiva-biotherapeutics"><img src="https://indexed.vc/api/badge/company/artiva-biotherapeutics" alt="Artiva Biotherapeutics on Indexed.vc" width="260" height="76" /></a>